Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

SVATON, Martin, Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK, Jana KREJCI, Marie DROSSLEROVA, Michal HRNCIARIK, Daniel HRICISAK, Alzbeta BEJCKOVA, Ondrej FISCHER, Martina VITKOVA a Maciej KRZAKOWSKI. Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab. In vivo. Athens: International Institute of Anticancer Research, 2024, roč. 38, č. 5, s. 2434-2440. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.13712.

Základní údaje

• Originální název: Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
• Autoři: SVATON, Martin (203 Česká republika), Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK (203 Česká republika, domácí), Jana KREJCI (203 Česká republika), Marie DROSSLEROVA (203 Česká republika), Michal HRNCIARIK (203 Česká republika), Daniel HRICISAK (203 Česká republika), Alzbeta BEJCKOVA (203 Česká republika), Ondrej FISCHER (203 Česká republika), Martina VITKOVA (203 Česká republika) a Maciej KRZAKOWSKI.
• Vydání: In vivo, Athens, International Institute of Anticancer Research, 2024, 0258-851X.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30203 Respiratory systems
• Stát vydavatele: Řecko
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 2.300 v roce 2022
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.21873/invivo.13712
• UT WoS: 001300248100042
• Klíčová slova anglicky: Non-small cell lung cancer; pembrolizumab; overall survival; PD-L1 expression
• Štítky: 14110215, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Background/Aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression >= 50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (>= 50%) >= 50%) in patients with NSCLC. Patients and Methods: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression >= 50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. Results: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD- L1 in the Cox regression model including the effect covariates. Conclusion: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD- L1 >= 50% >= 50% treated with pembrolizumab.